Medicines for dementia due to Alzheimer's disease and Parkinson's disease
Mattli R , Tzogiou C , Tomonaga Y , Sharakin M, Vinci L, Carlander M, Wirth B, Grobet C, Egli P, Nordström K, Gerber-Grote A, Puhan M, Wieser S
Record ID 32018002120
English
Details
Project Status:
Ongoing
URL for protocol:
https://www.bag.admin.ch/dam/bag/en/dokumente/kuv-leistungen/leistungen-und-tarife/hta/berichte/h0048alzh-hta-protocol.pdf.download.pdf/h0048alzh-hta-protocol.pdf
Anticipated Publish Date:
2022
URL for additional information:
https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-programm.html
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Switzerland
MeSH Terms
- Dementia
- Alzheimer Disease
- Parkinson Disease
- Drug Therapy
- Cholinesterase Inhibitors
- Rivastigmine
- Donepezil
- Galantamine
- Memantine
Keywords
- PROMs
- efficacy
- effectiveness
- safety
- costs
- economics
- cost-effectiveness
- budget impact
- legal
- social
- ethical
- organisational
- dementia
- alzheimer disease
- parkinson disease
Contact
Organisation Name:
Swiss Federal Office of Public Health (FOPH)
Contact Address:
Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name:
Stephanie Vollenweider
Contact Email:
hta@bag.admin.ch
Copyright:
Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.